Key clinical point: Performing left ventricular ejection fraction (LVEF) measurement before doxorubicin chemotherapy may not be helpful.
Major finding: Among diffuse large B-cell lymphoma (DLBCL) patients who had LVEF measured, the incidence of heart failure post treatment did not differ between patients who received doxorubicin and those who did not (P = 1.0).
Study details: A retrospective analysis of 291 patients diagnosed with DLBCL between 2001 and 2013.
Disclosures: The researchers reported having no competing interests.
Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85.
This Week's Must Reads
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology
Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21
Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8
5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21
Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025